Mechanism of cardioprotection by early ischemic preconditioning
- PMID: 20505987
- PMCID: PMC2932886
- DOI: 10.1007/s10557-010-6236-x
Mechanism of cardioprotection by early ischemic preconditioning
Abstract
A series of brief ischemia/reperfusion cycles (termed ischemic preconditioning, IPC) limits myocardial injury produced by a subsequent prolonged period of coronary artery occlusion and reperfusion. Over the last 2 decades our understanding of IPC's mechanism has increased exponentially. Hearts exposed to IPC have a better metabolic and ionic status during prolonged ischemia compared to naïve hearts. However, this difference is not thought to be the main mechanism by which IPC protects against infarction. Signaling pathways that are activated by IPC distinguish IPC hearts from naïve hearts. During the trigger phase of IPC, adenosine, bradykinin and opioid receptors are occupied. Although these three receptors trigger signaling through divergent pathways, the signaling converges on protein kinase C. We have proposed that at the end of the index ischemia the activated PKC sensitizes the low-affinity A(2b) adenosine receptor (A(2b)AR) through phosphorylation of either the receptor or its coupling proteins so that A(2b)AR can be activated by endogenous adenosine released by the previously ischemic cardiomyocytes. The sensitized A(2b)AR would then be responsible for activation of the survival kinases including PI3 kinase, Akt and ERK which then act to inhibit lethal mitochondrial permeability transition pore formation which normally uncouples mitochondria and destroys many myocytes in the first minutes of reperfusion. Herein we review the evidence for the above mechanisms and their functional details.
Similar articles
-
Protein kinase C protects preconditioned rabbit hearts by increasing sensitivity of adenosine A2b-dependent signaling during early reperfusion.J Mol Cell Cardiol. 2007 Sep;43(3):262-71. doi: 10.1016/j.yjmcc.2007.05.016. Epub 2007 May 24. J Mol Cell Cardiol. 2007. PMID: 17632123 Free PMC article.
-
Evidence that the acute phase of ischemic preconditioning does not require signaling by the A 2B adenosine receptor.J Mol Cell Cardiol. 2010 Nov;49(5):886-93. doi: 10.1016/j.yjmcc.2010.08.015. Epub 2010 Aug 24. J Mol Cell Cardiol. 2010. PMID: 20797398 Free PMC article.
-
Cardioprotective PKG-independent NO signaling at reperfusion.Am J Physiol Heart Circ Physiol. 2010 Dec;299(6):H2028-36. doi: 10.1152/ajpheart.00527.2010. Epub 2010 Sep 17. Am J Physiol Heart Circ Physiol. 2010. PMID: 20852051 Free PMC article.
-
Signaling pathways in ischemic preconditioning.Heart Fail Rev. 2007 Dec;12(3-4):181-8. doi: 10.1007/s10741-007-9025-2. Heart Fail Rev. 2007. PMID: 17516169 Review.
-
Mitochondria and GSK-3beta in cardioprotection against ischemia/reperfusion injury.Cardiovasc Drugs Ther. 2010 Jun;24(3):255-63. doi: 10.1007/s10557-010-6234-z. Cardiovasc Drugs Ther. 2010. PMID: 20490903 Review.
Cited by
-
Hypoxia-inducible factor 1 transcriptional activity in endothelial cells is required for acute phase cardioprotection induced by ischemic preconditioning.Proc Natl Acad Sci U S A. 2012 Jun 26;109(26):10504-9. doi: 10.1073/pnas.1208314109. Epub 2012 Jun 13. Proc Natl Acad Sci U S A. 2012. PMID: 22699503 Free PMC article.
-
A2B adenosine receptors inhibit superoxide production from mitochondrial complex I in rabbit cardiomyocytes via a mechanism sensitive to Pertussis toxin.Br J Pharmacol. 2011 Jul;163(5):995-1006. doi: 10.1111/j.1476-5381.2011.01288.x. Br J Pharmacol. 2011. PMID: 21366548 Free PMC article.
-
Dynamic Regulation of Cysteine Oxidation and Phosphorylation in Myocardial Ischemia-Reperfusion Injury.Cells. 2021 Sep 11;10(9):2388. doi: 10.3390/cells10092388. Cells. 2021. PMID: 34572037 Free PMC article. Review.
-
Novel therapeutic strategies for ischemic heart disease.Pharmacol Res. 2014 Nov;89:36-45. doi: 10.1016/j.phrs.2014.08.004. Epub 2014 Sep 1. Pharmacol Res. 2014. PMID: 25193582 Free PMC article. Review.
-
Pre-conditioning with PQQ during pregnancy alleviates LPS-induced placental damage and improves the fetal survival and growth in mice.Front Endocrinol (Lausanne). 2025 Jul 10;16:1617026. doi: 10.3389/fendo.2025.1617026. eCollection 2025. Front Endocrinol (Lausanne). 2025. PMID: 40708725 Free PMC article.
References
-
- Cohen MV, Downey JM. Myocardial preconditioning promises to be a novel approach to the treatment of ischemic heart disease. Annu Rev Med. 1996;47:21–9. - PubMed
-
- Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation. 1986;74:1124–36. - PubMed
-
- Murry CE, Richard VJ, Jennings RB, Reimer KA. Myocardial protection is lost before contractile function recovers from ischemic preconditioning. Am J Physiol. 1991;260:H796–804. - PubMed
-
- Jennings RB, Sebbag L, Schwartz LM, et al. Metabolism of preconditioned myocardium: effect of loss and reinstatement of cardioprotection. J Mol Cell Cardiol. 2001;33:1571–88. - PubMed
-
- Fleet WF, Johnson TA, Graebner CA, Gettes LS. Effect of serial brief ischemic episodes on extracellular K+, pH, and activation in the pig. Circulation. 1985;72:922–32. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous